Last Updated: August 27, 2026
The landscape of GLP-1 weight loss therapy has shifted from simple "medication access" to a choice between two distinct philosophies: lean, medication-first delivery and high-touch, behavioral health integration. For consumers navigating this in 2026, two of the most prominent names represent these opposite ends of the spectrum: OrderlyMeds and Noom Med.
OrderlyMeds is a medication-centric platform built for patients who prioritize direct access to compounded semaglutide and tirzepatide at flat, transparent rates. Noom Med, the clinical extension of the globally recognized Noom psychology app, offers a more comprehensive metabolic health program that wraps prescriptions in daily coaching, cognitive behavioral therapy (CBT) lessons, and dietitian support.
To help you decide which model fits your health goals and budget, we’ve analyzed both providers using the official GLP-1 Reviews weighted scoring methodology.
Quick Comparison: OrderlyMeds vs. Noom Med (2026)
| Feature | OrderlyMeds | Noom Med |
|---|---|---|
| GLP-1 Reviews Score | 4.1 / 5.0 | 4.5 / 5.0 |
| Official Tier | Strong Choice | Top Tier |
| Published Price Range | $83-$399/mo | $99-$279/month |
| Key Compounded Pricing | Compounded semaglutide $224/3 months ( |
Range published on live review page; intake walkthrough shows $129 due today then $249/mo recurring |
| Brand Pricing | Zepbound $1,498/mo; Wegovy $1,839/mo | Brand-name options available; live review page lists overall $99-$279/month range |
| Insurance | No insurance accepted | Insurance concierge |
| Prescriber Model | Asynchronous / telehealth | App-integrated with personalized low-and-slow titration |
| Support Level | Medication-focused; no dietitian access | Extensive (coaching + dietitian) |
| Geographic Availability | Nationwide (US) | Nationwide (US) |
| Key Drugs Available | Compounded semaglutide, compounded tirzepatide, Zepbound, Wegovy | Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide |
At-a-Glance: 3 Key Differences
- Behavioral Depth: Noom Med includes a 55-screen clinical intake and a psychology-based curriculum; OrderlyMeds uses a streamlined, 6-screen asynchronous intake focused primarily on eligibility and prescription.
- Pricing Structure: OrderlyMeds’ live review page publishes a broad $83-$399/mo range with multi-month discount pricing for compounded options; Noom Med’s live review page publishes a $99-$279/month range for comparison.
- Clinical Rigor: Noom Med performs a deeper clinical screen, including gastrointestinal (GI) baselines and muscle retention awareness, whereas OrderlyMeds keeps onboarding lower-friction and more medication-focused.
2026 Pricing Comparison: The True Cost of Care
In the GLP-1 market, "price" is rarely just the number on the checkout page. It includes the drug, the provider access, and the support layers.
OrderlyMeds: Flat-Rate Transparency
OrderlyMeds has positioned itself as a low-friction, medication-first option for self-pay patients. On the live review page, the published comparable range is $83-$399/mo, with pricing built around multi-month discounts rather than a separate membership fee.
- Compounded Semaglutide: $224 per 3 months (about $75/month).
- Compounded Tirzepatide: $449 per 3 months (about $150/month).
- Branded Options: Zepbound $1,498/month and Wegovy $1,839/month.
- Insurance: No insurance accepted.
Retrieval Date: August 27, 2026, via the live OrderlyMeds review page at GLP-1 Reviews
Noom Med: Value Through Integration
Noom Med is priced above bare-bones prescription access because it combines medication support with the Noom app, coaching, dietitian access, and insurance concierge. For apples-to-apples comparison, the live review page lists a published range of $99-$279/month.
- Published Comparable Range: $99-$279/month.
- Insurance Support: Insurance concierge is available for patients pursuing branded GLP-1 coverage.
- Dietitian Access: Included.
- Note on Intake Pricing: The intake walkthrough shows $129 due today, then $249/month recurring, but the live review page range is the more appropriate figure for this side-by-side comparison.
Retrieval Date: August 27, 2026, via the live Noom Med review page at GLP-1 Reviews
Drugs Available: Formularies Compared
Both platforms provide access to the industry leaders: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound): but their sourcing and variety differ.
OrderlyMeds Formulary
OrderlyMeds focuses on a narrower medication menu centered on injections:
- Compounded Semaglutide (Injections)
- Compounded Tirzepatide (Injections)
- Brand-name Wegovy
- Brand-name Zepbound
The live review page supports positioning OrderlyMeds as a compounded-first provider. In the intake walkthrough, pharmacy partners are referenced as Pharmacy Hub or SmartPharmaRx, but specific partners are not publicly named.
Noom Med Formulary
As a Top Tier provider with 4.8 Clinical Quality, Noom Med offers a broader GLP-1 menu:
- Compounded Semaglutide (Injections)
- Brand-name GLP-1s: Ozempic, Wegovy, Mounjaro, and Zepbound
- Personalized low-and-slow titration: The intake walkthrough presents this as a tailored path for patients who may be more sensitive to side effects.
Prescriber Model & Clinical Rigor
How you interact with your doctor: and how much they know about you before you start: is where these two platforms diverge most sharply.
The OrderlyMeds Flow: Speed Over Depth
OrderlyMeds uses an asynchronous intake model. Our editorial walkthrough of the OrderlyMeds funnel revealed a very low-friction experience:
- Eligibility: Height, weight, and age.
- Selection: You choose your medication tier before the detailed medical history.
- Payment: A credit card is collected to "secure" the order before the clinical screening.
- Review: A licensed provider reviews the health questionnaire and issues a prescription if eligible.
This model is ideal for patients who have already discussed GLP-1s with a primary care physician and simply want a reliable, low-cost fulfillment channel.
The Noom Med Flow: Clinical Safety First
Noom Med’s intake is widely regarded as one of the most comprehensive in the industry. It consists of 55 screens and takes approximately 10 minutes to complete. Key clinical features include:
- GI Baseline: They ask for the frequency of 8 different GI symptoms before you start.
- Muscle Defense: Questions about resistance training and protein intake to prevent sarcopenia (muscle loss).
- Psychological Screening: A dedicated eating-disorder screen and nausea-related tolerance assessment.
Because of this rigor, Noom Med holds a 4.8 Clinical Quality score and a 4.9 Support score, making it a more Top Tier selection for those with complex medical histories.
Patient Experience: App vs. Portal
OrderlyMeds: The "Med-Only" Utility
The OrderlyMeds experience is primarily transactional. You log into a portal to manage refills, track shipping, and message your provider. There is no "OrderlyMeds App" with daily lessons or calorie tracking. The bigger tradeoff is that the live review page indicates no dietitian access and no lab testing.
Noom Med: The Behavioral Ecosystem
Noom Med is built into the existing Noom app. Patients receive:
- Daily Lessons: Psychology-based content designed to rewire the brain's relationship with food.
- Human Coaching: Access to a coach for motivation and habit tracking.
- Dietitian Support: Included in the membership to help manage the "GLP-1 diet" (high protein, fiber, and hydration).
- Personalized low-and-slow titration: A tailored approach described in the intake walkthrough for patients who may need slower dose escalation.
Geographic Availability & Speed to Start
Both platforms are widely available, but their "Speed to Start" differs based on the complexity of their clinical review.
- OrderlyMeds: Fast. Because the intake is asynchronous and streamlined, it generally offers a lower-friction path to getting started. They serve almost all US states.
- Noom Med: Moderate. The 55-screen intake and more intensive clinical review process mean it can take slightly longer to reach the "shipped" status, but that added screening may be worthwhile for patients who want more structure.
Customer Service & Refund Policies
Trust and transparency are vital when dealing with compounded medications.
- OrderlyMeds: The live review page shows Trustpilot 3.7 across 480+ reviews, and CoA status unknown. Patients considering compounded medication should weigh that transparency profile against the platform’s lower-cost pricing.
- Noom Med: Noom is a legacy brand with Trustpilot 4.5 across 66,000+ reviews. Its scale and established app ecosystem help explain why it remains a Top Tier option despite a more involved onboarding process.
Best for [Scenario]: Which Should You Choose?
Best for Cash-Pay Buyers on a Budget: OrderlyMeds
If you are paying out of pocket and want a lower-cost, medication-focused option without paying for coaching or dietitian access, OrderlyMeds stands out. Its live review page lists compounded semaglutide at $224 per 3 months (~$75/month) and compounded tirzepatide at $449 per 3 months (~$150/month), which keeps it in Strong Choice territory for cost-conscious self-pay buyers.
Best for Patients Who Need Behavior Change: Noom Med
If you have struggled with "yo-yo dieting" and want to ensure the weight stays off after you stop the medication, Noom Med’s Top Tier behavioral integration is the stronger fit. The psychology lessons, coaching, and dietitian access provide more day-to-day structure.
Best for Complex Medical Histories: Noom Med
Because of its 55-screen intake, GI baseline assessments, and stronger support infrastructure, Noom Med is better suited for patients who have pre-existing digestive issues or concerns about side effects like nausea and muscle loss.
Best for "Medication-Only" Pros: OrderlyMeds
If you are already comfortable with GLP-1 treatment and simply want a lower-friction route to medication access, OrderlyMeds provides a streamlined, professional experience.
Patient Experience Signals: Trustpilot
Public-facing review signals do not tell you everything about clinical quality, but they do help frame what kind of customer experience you may be buying into. For a comparison like OrderlyMeds vs. Noom Med, those signals matter because the two companies operate at very different scale and with very different care models.
For OrderlyMeds, the live review page shows Trustpilot 3.7 across 480+ reviews. For a compounded-first, self-pay provider, that profile does not automatically mean the service is unsafe or unusable. It does mean patients should go in with more questions. A mid-range Trustpilot score suggests that some patients are satisfied with the low-friction access model, while others may have run into problems around expectations, refill timing, or support response. Because OrderlyMeds is built for convenience and lower-cost access, trust depends heavily on how comfortable you are with a lighter-touch experience and less publicly disclosed sourcing detail.
For Noom Med, the live review page points to Trustpilot 4.5 across 66,000+ reviews. That does not mean every GLP-1 patient will have a perfect experience, but it does suggest a much larger and more established customer-service infrastructure. Noom benefits from legacy brand recognition, a mature app ecosystem, and a broader behavioral-health platform that many users already know before they ever consider medication. In practical terms, those signals may make some first-time GLP-1 users feel more comfortable, especially if they want a platform with a long digital track record and more visible public feedback.
The right takeaway is not that one review site score should make the decision for you. Instead, treat Trustpilot as context. They can help you judge operational maturity, support consistency, and reputation at scale, but they do not replace a clinical conversation with a licensed prescriber about whether GLP-1 treatment is appropriate for your health history.
Editorial illustration comparing patient review signals, trust ratings, and accreditation-style reputation cues for OrderlyMeds vs. Noom Med.
Side Effects and Safety Considerations
No matter which platform you choose, GLP-1 therapy comes with a side-effect profile that patients should understand before enrolling. The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and reduced appetite. These symptoms are often most noticeable during dose escalation, when the medication is increased and the body is still adjusting.
Both OrderlyMeds and Noom Med require a prescription from a licensed clinician, but the way they screen patients differs. OrderlyMeds uses a low-friction asynchronous intake that is designed to move patients through eligibility and prescription review quickly. That may appeal to experienced GLP-1 users who already know what treatment path they want. The tradeoff is that the public onboarding experience is lighter and less clinically detailed.
Noom Med, by contrast, uses a 55-screen clinical intake that includes GI baselines and eating-disorder screening. That deeper front-end process may be helpful for patients who are worried about tolerability, have a more complex health history, or want a provider experience that surfaces side-effect concerns before treatment starts.
Neither model eliminates the risk of side effects. Patients should know how to respond if symptoms linger or become more disruptive. If nausea, vomiting, constipation, or diarrhea is persistent, or if side effects begin to interfere with hydration, nutrition, or daily functioning, contact the prescribing clinician. If you develop severe abdominal pain, repeated vomiting, or signs of dehydration, seek urgent medical evaluation rather than waiting for a routine portal reply.
The bottom line is simple: convenience matters, but safe GLP-1 use also depends on how quickly you can recognize side effects, communicate with your prescriber, and get appropriate guidance if symptoms escalate.
Medical illustration highlighting common GLP-1 gastrointestinal side effects and safety considerations relevant to OrderlyMeds and Noom Med patients.
Medication Sourcing and Regulatory Context
One of the biggest differences in today’s GLP-1 market is the distinction between FDA-approved brand-name drugs and compounded alternatives. Brand-name products such as Wegovy, Zepbound, Ozempic, and Mounjaro are FDA-approved medications with manufacturer-controlled labeling, dose forms, and distribution channels. When a platform offers those products, the patient is generally working within the standard branded supply chain, even if affordability or insurance approval remains a separate challenge.
Compounded products work differently. Compounded semaglutide and compounded tirzepatide are prepared by state-licensed compounding pharmacies rather than sold as FDA-approved brand-name products. Patients often consider compounded options because of price, access, or convenience, especially in self-pay settings. That is the core appeal of OrderlyMeds, whose live review page supports its positioning as a compounded-first provider. At the same time, the live page notes that pharmacy partners are not publicly named, and CoA status is listed as unknown. That does not prove a quality problem, but it does create an extra layer of diligence for patients who want more transparency before enrolling.
Noom Med sits in a different position. Its live review page supports access to brand-name GLP-1s as well as compounded semaglutide. For some patients, that broader menu may be useful because it leaves open both insurance-driven branded paths and self-pay compounded options inside one platform.
A Certificate of Analysis (CoA) is a document that helps verify testing and quality-control information for a medication batch or ingredient. Patients considering compounded treatment should understand whether sourcing and testing documentation is available, who the dispensing pharmacy is, and what safeguards are in place if a shipment issue or product concern comes up. Before enrolling in any compounded-first program, ask directly how the medication is sourced, which pharmacy dispenses it, and what documentation can be provided if you want to verify quality standards for yourself.
What to Ask Before Enrolling
A comparison table is useful, but it should not be the last step before checkout. The better approach is to turn the published data into a short list of practical questions for each platform.
For OrderlyMeds, start with the dispensing side. Ask which pharmacy will actually fill your prescription, since the live review page indicates that specific partners are not publicly named. Next, ask for the effective monthly price at your prescribed dose, especially if you are comparing multi-month discounts against a single-month mental benchmark. The published range is broad, and the compounded offers are framed around three-month pricing, so it is worth confirming what you will really pay over time. You should also ask what the card-on-file pre-authorization model means in practice. Specifically, when is your card charged, what happens if a clinician decides you are not an appropriate candidate, and how are exceptions handled? Because OrderlyMeds is built around convenience, you should also ask what happens if a shipment is delayed, how refill timing works, and what the current cancellation terms are before you commit.
For Noom Med, begin with plan fit. Ask which plan inside the published $99-$279/month range matches your likely medication path, because that range spans more than one type of experience. If you are hoping to use insurance for a brand-name medication, ask exactly how the insurance concierge handles a denied prior authorization and what the fallback path looks like. Since the article establishes that dietitian access is included, confirm whether that access applies to the specific plan you are selecting and how often you can actually use it. Because lab testing is not included, ask how to arrange bloodwork if a clinician wants monitoring before or during treatment. Finally, review the billing-cycle terms before checkout, especially if any portion of the program renews on a monthly or bundled basis.
These questions will not make the decision for you, but they will reduce surprises. In a market where pricing, support, and sourcing can vary widely, the best enrollment strategy is to clarify the operational details before your card is charged.
FAQ: OrderlyMeds vs Noom Med
Does insurance cover OrderlyMeds or Noom Med?
OrderlyMeds does not accept insurance; it is a 100% self-pay/cash-pay platform. Noom Med offers an Insurance Concierge service to help patients pursue coverage for brand-name medications such as Wegovy or Zepbound.
Are the medications from OrderlyMeds and Noom Med safe?
Both providers require a prescription from a licensed clinician, but the sourcing details publicly disclosed on their live review pages are different. OrderlyMeds is a compounded-first provider, but specific pharmacy partners are not publicly named on the live page. Noom Med’s live page supports access to both brand-name GLP-1s and compounded semaglutide.
Can I cancel my subscription at any time?
OrderlyMeds is positioned as a straightforward self-pay option, while Noom Med uses a more program-based model. In either case, patients should review the current cancellation and billing terms before checkout, especially if multi-month pricing is involved.
Which is faster to get started?
OrderlyMeds is generally faster to start because its intake is lower-friction and more medication-focused. Noom Med usually takes longer because the onboarding is more extensive and includes deeper clinical screening.
The GLP-1 Reviews Verdict
Both OrderlyMeds and Noom Med are highly rated on our platform, but they serve different needs.
OrderlyMeds (Score: 4.1) is a Strong Choice for the savvy, self-sufficient consumer who wants lower-cost, self-pay medication access with minimal added program layers.
Noom Med (Score: 4.5) is a Top Tier provider for the patient who wants a more holistic transformation. By combining GLP-1 care with behavior change psychology, coaching, and dietitian access, they offer a more comprehensive path to metabolic health.
To compare these against 76 other options, visit our GLP-1 Provider Directory or see our picks for the Cheapest GLP-1 Programs.
Corrected 9 October 2026. We removed 4 generated images from this article, including an “Accredited Practice” seal that no accreditor issued. Generated images on this site no longer show certifications, organisations, products, prices or figures unless the specific claim has been checked.
Corrected 14 October 2026: this article previously gave Better Business Bureau ratings for providers it compares, taken from our April 2026 research. We kept no record of where those ratings came from, so they have been removed.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Keep exploring our GLP-1 resources:
